NYSE:MRKMerck & Co., Inc. Stock Price, Forecast & News

Merck & Co., Inc.'s stock was trading at $79.25 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MRK stock has increased by 3.0% and is now trading at $81.62. View which stocks have been most impacted by Coronavirus.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 4 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Merck & Co., Inc..

Merck & Co., Inc. is scheduled to release its next quarterly earnings announcement on Tuesday, April 28th 2020. View our earnings forecast for Merck & Co., Inc..

Merck & Co., Inc. will be holding an earnings conference call on Tuesday, April 28th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Merck & Co., Inc. (NYSE:MRK) posted its quarterly earnings data on Wednesday, February, 5th. The company reported $1.16 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $1.15 by $0.01. The firm earned $11.87 billion during the quarter, compared to analysts' expectations of $11.71 billion. Merck & Co., Inc. had a return on equity of 49.41% and a net margin of 21.01%. The company's quarterly revenue was up 7.9% compared to the same quarter last year. During the same period last year, the business earned $1.04 earnings per share. View Merck & Co., Inc.'s earnings history.

Merck & Co., Inc. declared a quarterly dividend on Wednesday, January 29th. Investors of record on Monday, March 16th will be paid a dividend of $0.61 per share on Tuesday, April 7th. This represents a $2.44 annualized dividend and a yield of 2.99%. The ex-dividend date is Friday, March 13th. View Merck & Co., Inc.'s dividend history.

Merck & Co., Inc. announced that its Board of Directors has initiated a share repurchase program on Thursday, October 25th 2018, which authorizes the company to buyback $10,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to purchase up to 5.1% of its shares through open market purchases. Shares buyback programs are usually an indication that the company's management believes its shares are undervalued.

Merck & Co., Inc. issued an update on its FY20 earnings guidance on Wednesday, February, 5th. The company provided earnings per share guidance of $5.62-5.77 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.54. The company issued revenue guidance of $48.8-50.3 billion, compared to the consensus revenue estimate of $48.65 billion.

16 brokers have issued twelve-month target prices for Merck & Co., Inc.'s shares. Their forecasts range from $84.00 to $105.00. On average, they expect Merck & Co., Inc.'s stock price to reach $94.00 in the next year. This suggests a possible upside of 15.2% from the stock's current price. View analysts' price targets for Merck & Co., Inc..

News coverage about MRK stock has trended very negative on Wednesday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Merck & Co., Inc. earned a news sentiment score of -3.3 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutMerck & Co., Inc..

Merck & Co., Inc. saw a drop in short interest during the month of March. As of March 13th, there was short interest totaling 18,162,700 shares, a drop of 12.6% from the February 27th total of 20,780,000 shares. Based on an average trading volume of 10,770,000 shares, the days-to-cover ratio is presently 1.7 days. Approximately 0.7% of the shares of the stock are short sold. View Merck & Co., Inc.'s Current Options Chain.

Some companies that are related to Merck & Co., Inc. include Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Allergan (AGN), Zoetis (ZTS), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Zogenix (ZGNX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include AT&T (T), Pfizer (PFE), Johnson & Johnson (JNJ), Walt Disney (DIS), Intel (INTC), Cisco Systems (CSCO), Verizon Communications (VZ), JPMorgan Chase & Co. (JPM), AbbVie (ABBV) and Exxon Mobil (XOM).

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Merck & Co., Inc.'s stock is owned by many different retail and institutional investors. Top institutional shareholders include Cacti Asset Management LLC (0.03%), Radnor Capital Management LLC (0.02%), State of Alaska Department of Revenue (0.02%), Park National Corp OH (0.01%), Neville Rodie & Shaw Inc. (0.01%) and Foundation Resource Management Inc. (0.01%). Company insiders that own Merck & Co., Inc. stock include Adam H Schechter, Ashley Watson, Frank Clyburn, Julie L Gerberding, Kenneth C Frazier, Leslie A Brun, Merck & Co, Inc, Richard R Deluca, Rita A Karachun, Robert M Davis, Roger M Perlmutter, Sanat Chattopadhyay, Thomas H Glocer, Weir Mirian M Graddick and Wendell P Weeks. View institutional ownership trends for Merck & Co., Inc..

MRK stock was sold by a variety of institutional investors in the last quarter, including Foundation Resource Management Inc., Centre Asset Management LLC, First Financial Bank Trust Division, Radnor Capital Management LLC, Cacti Asset Management LLC, Park National Corp OH, Private Trust Co. NA, and First National Bank of Mount Dora Trust Investment Services. Company insiders that have sold Merck & Co., Inc. company stock in the last year include Frank Clyburn, Julie L Gerberding, Richard R Deluca, and Robert M Davis. View insider buying and selling activity for Merck & Co., Inc..

MRK stock was purchased by a variety of institutional investors in the last quarter, including Fulton Bank N.A., Cardinal Capital Management Inc., State of Alaska Department of Revenue, IBM Retirement Fund, Investment House LLC, Gradient Investments LLC, Adviser Investments LLC, and CHICAGO TRUST Co NA. View insider buying and selling activity for Merck & Co., Inc..

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MRK stock can currently be purchased for approximately $81.62.

Merck & Co., Inc. has a market capitalization of $207.01 billion and generates $46.84 billion in revenue each year. The company earns $9.84 billion in net income (profit) each year or $5.19 on an earnings per share basis. Merck & Co., Inc. employs 71,000 workers across the globe. View additional information about Merck & Co., Inc..

The official website for Merck & Co., Inc. is http://www.merck.com/.

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at 908-740-4000 or via email at [email protected]